Merck vs Pfizer MRK vs PFE
Merck and Pfizer on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- One-year price return: Merck +73.9%, Pfizer +22.1%.
- Trailing P/E: Merck 116.8×, Pfizer 38.9×.
- Market value: Merck $360.12B, Pfizer $168.60B.
- Price / sales: Merck 5.4×, Pfizer 2.6×.
Price return
2025-10-16 → 2026-10-16
MRK+73.9%
PFE+22.1%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$360.12B
$168.60B
Enterprise value
$407.18B
$230.81B
Employees
74,000
75,000
Revenue per employee (TTM)
$900K
$849K
Our models
nightlythe valuation on each stock's pagePrice vs model
24% undervalued vs model
3% undervalued vs model
Model range
$113–474
$12.41–64.63
Models in the headline
1
1
FCF growth priced in, at a 10% return
18.2%
14.0%
Every model, its assumptions and its range: MRK valuation · PFE valuation. The growth priced in, at any return: MRK reverse DCF · PFE reverse DCF.
Trading
close 2026-10-16Last close
$145.95
$29.58
52-week high
$156.45
$29.58
52-week low
$82.49
$23.67
Price vs 52-week high
−6.7%
0.0%
Price vs 52-week low
+76.9%
+25.0%
Average daily volume / shares
0.4%
0.7%
Beta
0.22
0.28
Returns
to 2026-10-161 month
+0.7%
+7.7%
3 months
+14.4%
+17.7%
6 months
+26.4%
+8.7%
Year to date
+38.7%
+18.8%
1 year
+73.9%
+22.1%
1 year, dividends added
+78.0%
+29.2%
2 years
+32.2%
−0.3%
Valuation
price × TTM to Jun 2026P/E (TTM)
116.8×
38.9×
P/E on consensus EPS (next FY)
54.9×
10.0×
Price / sales
5.4×
2.6×
EV / sales
6.1×
3.6×
EV / EBITDA
—
—
Price / book
8.6×
2.0×
Price / free cash flow (FY)
29.1×
18.6×
Free-cash-flow yield (FY)
3.4%
5.4%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+3.2%
−0.5%
Revenue, 3-year CAGR
3.1%
−12.0%
Revenue, 5-year CAGR
6.3%
8.3%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
−63.5%
+117.7%
EPS, 3-year CAGR
8.4%
−37.1%
Free cash flow, 3-year CAGR
−5.6%
−29.6%
Diluted shares, 3-year change
−1.4%
−0.3%
Profitability
TTM to Jun 2026Gross margin (FY)†
72.0%
70.3%
Operating margin
—
—
EBITDA margin
—
—
Net margin
4.8%
6.8%
Free-cash-flow margin (FY)
19.0%
14.5%
Return on equity
7.6%
5.1%
Return on assets
2.4%
2.2%
Asset turnover
0.51
0.32
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$6.85B
$976.0M
Total debt
$53.91B
$63.19B
Net debt
$47.06B
$62.22B
Debt / equity
1.3×
0.7×
Net debt / EBITDA (TTM)
—
—
Interest coverage (FY)
17.3×
5.8×
Current ratio (FY)
1.54
1.16
Dividends
trailing 12 monthsDividend yield
2.3%
5.8%
Dividends per share
$3.40
$1.72
Payout ratio (of TTM EPS)
272.0%
226.3%
Dividend per share, 5-year CAGR
6.0%
2.1%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
11
11
Insider open-market buys (Form 4)
$0
$3.0M
Insider sales (Form 4)
$30.0M
$83K
Analyst upgrades
2
0
Analyst downgrades
1
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$66.57B
$63.70B
EBITDA
—
—
Operating income
—
—
Net income
$3.17B
$4.33B
EPS (diluted)
$1.25
$0.76
Operating cash flow
$16.47B
$11.70B
Capital expenditure
−$4.11B
−$2.63B
Free cash flow
$12.36B
$9.07B
Dividends paid
$8.18B
—
Statements from the companies' SEC filings; prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.